Stathmin overexpression identifies high risk for lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 5, 2014, Pages 944-950

  Akhtar, Javed ^a   Wang, Zhou ^a   Jiang, Wen Peng ^a   Bi, Ming Ming ^a   Zhang, Zhi Ping ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Lymphatic metastatic recurrence; Stathmin 1

Indexed keywords

POLYCLONAL ANTIBODY; STATHMIN; STMN1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RISK FACTOR; SURVIVAL RATE; WESTERN BLOTTING; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; SECONDARY; TUMOR RECURRENCE;

CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK; STATHMIN;

EID: 84898922560     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12498     Document Type: Article

References (37)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int. J. Cancer 2010; 127: 2893-2917.
2. Song Y, Wang Z, Liu X, Jiang W, Shi M. CCR7 and VEGF-C: molecular indicator of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy? Ann. Surg. Oncol. 2012; 19: 3606-3612. Pubmed Central PMCID: 22644515.
3. Sobel A. Stathmin: a relay phosphoprotein for multiple signal transduction. Trends Biochem. Sci. 1991; 16 (8): 301-305.
4. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev. Anticancer Ther. 2008; 8: 1461-1470.
5. Akhtar J, Wang Z, Zhang ZP, Bi MM. Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo. J. Transl. Med. 2013; 11: 212.
6. Trovik J, Wik E, Stefansson IM etal. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin. Cancer Res. 2011; 17: 3368-3377.
7. Akhtar J, Wang Z, Yu C, Zhang ZP, Bi MM. STMN-1 gene: a predictor of survival in stage IIA esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy? Ann. Surg. Oncol. 2014; 21: 315-321.
8. Wang Z, Liu X-Y, Liu F-Y, Chen J-H. A study of correlation between early postoperative relapse with lymph node micrometastasis in patients with N0 esophageal cancer. Zhonghua Wai Ke Za Zhi 2004; 42 (2): 68-71.
9. Shimada H, Kitabayashi H, Nabeya Y etal. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003; 133 (1): 24-31.
10. Greenlee DRT, Hill-Harmon MMB, Murray MT, Thun DM. Cancer statistics, 2001. CA Cancer J. Clin. 2001; 51 (1): 15-36.
11. Nakagawa S, Kanda T, Kosugi S-I, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J. Am. Coll. Surg. 2004; 198: 205-211.
12. Tanabe G, Baba M, Kuroshima K etal. Clinical evaluation of the esophageal lymph flow system based on RI uptake of dissected regional lymph nodes following lymphoscintigraphy. Nihon Geka Gakkai Zasshi 1986; 87: 315-323.
13. Chen G, Wang Z, Liu X-Y, Zhang M-Y, Liu F-Y. Abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma. World J. Surg. 2009; 33: 278-283.
14. Li B, Chen H, Xiang J etal. Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: a single-institution experience. J. Thorac. Cardiovasc. Surg. 2012; 144: 778-785.
15. Huang W, Lie B, Gong H etal. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases. Radiother. Oncol. 2010; 95: 229-233.
16. Olsen JR, Dehdashti F, Siegel BA, Zighelboim I, Grigsby PW, Schwarz JK. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET. Int. J. Radiat. Oncol. Biol. Phys. 2011; 18: 772-777.
17. Hulscher JBF, Sandick JWV, Boer AGEMD etal. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N. Engl. J. Med. 2002; 347: 1662-1669.
18. Goldminc M, Maddern G, Prise EL, Meunier B, Campion J, Launois B. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br. J. Surg. 1993; 80: 367-370.
19. Gu Y, Swisher SG, Ajani JA etal. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006; 106: 1017-1025.
20. Natsugoe S, Yoshinaka H, Shimada M etal. Number of lymph node metastases determined by presurgical ultrasound and endoscopic ultrasound is related to prognosis in patients with esophageal carcinoma. Ann. Surg. 2001; 234: 613-618.
21. Baba M, Aikou T, Natsugoe S etal. Quality of life following esophagectomy with three-field lymphadenectomy for carcinoma, focusing on its relationship to vocal cord palsy. Dis. Esophagus 1998; 11 (1): 28-34.
22. Matsubara T, Ueda M, Takahashi T, Nakajima T, Nishi M. Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J. Am. Coll. Surg. 1996; 182: 340-346.
23. Tachibana M, Kinugasa S, Yoshimura H etal. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am. J. Surg. 2005; 189: 98-109.
24. Fujita H, Sueyoshi S, Tanaka T, Shirouzu K. Three-field dissection for squamous cell carcinoma in the thoracic esophagus. Ann. Thorac. Cardiovasc. Surg. 2002; 8: 328-335.
25. Dresner SM, Griffin PSM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br. J. Surg. 2000; 87: 1426-1433.
26. Chen G, Wang Z, Liu X-Y, Liu F-Y. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J. Surg. 2007; 31: 1107-1114.
27. Fujita H, Kakegawa T, Yamana H etal. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann. Surg. 1995; 222: 654-662.
28. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br. J. Cancer 2000; 83: 311-318.
29. Chen G, Wang Z, Liu X-Y, Zhang M-Y, Liu F-Y. Clinical study of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus. Eur. J. Cardiothorac Surg. 2009; 35 (1): 1-7.
30. Chen G, Wang Z, Liu X-Y, Liu F-Y. Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma? Ann. Thorac. Surg. 2009; 87: 1697-1702.
31. Kuo M-F, Wang H-S, Kuo Q-T etal. High expression of stathmin protein predicts a fulminant course in medulloblastoma. J. Neurosurg. Pediatr. 2009; 4: 74-80.
32. Kouzu Y, Uzawa K, Koike H etal. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br. J. Cancer 2006; 94: 717-723.
33. Saal LH, Johansson P, Holm K etal. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 7564-7569.
34. Golouh R, Cufer T, Sadikov A etal. The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res. Treat. 2008; 110: 317-326.
35. Lin W-C, Chen S-C, Hu F-C etal. Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology 2009; 74: 1264-1269.
36. Su D, Smith SM, Preti M etal. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009; 115: 2453-2463.
37. Xi W, Rui W, Fang L, Ke D, Ping G, Hui-Zhong Z. Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J. Cancer Res. Clin. Oncol. 2009; 135: 837-846.